Stem Cell Stocks

[DFLY]

SWEET!!!!!!!!!!!!!!!)Stemmie time!)))

[nsomniyak]

This report has triggered an after hours rally in the stem cell stocks.

Question for the board - which stocks are poised to react best to this next week?

[swanlinbar]

STEM CELLS - Obama To Overturn Ban On Federal Funding For Stem Cell Research

BEN FELLER | March 6, 2009 04:21 PM EST | AP

WASHINGTON — President Barack Obama is expected to sign an executive order on Monday reversing restrictions on federal funding of embryonic stem cell research. A senior administration official says the president will hold an event at the White House to announce the move. The official spoke on condition of anonymity because the policy had not yet been publicly announced on Friday.

Stem cells are the building blocks that turn into different kinds of tissue.

Under President George W. Bush, federal money for research on human embryonic stems cells was limited to those stem cell lines that were created before Aug. 9, 2001. No federal dollars could be used on research with cell lines from embryos destroyed from that point forward.

[DFLY]

isco? i was hopin fer a bucker break at some point soon.. tough ta say really though.. hopefully mms let it blast off next week.Have a g1.

[Gastrodamas]

Whats the cahnce this hits 80-90 cents?

[Gastrodamas]

starting to look interesting.

[DFLY]

FYI ISCO waking outta nowhere .50 HOD now...hmm..eom

[DFLY]

nice thanks bro!)

[Epic]

Stem news

http://www.nytimes.com/2009/02/27/us/politics/27brfs-STEMCELLBILL_BRF.html

http://uk.reuters.com/article/scienceNews/idUKTRE51P7ZQ20090226

[DFLY]

btw Stem Cell Bills in Congress



[1]
S. 99 (is) To amend the Internal Revenue Code of 1986 to provide a Federal income tax credit for certain stem cell research expenditures. [Introduced in Senate]
Size: 7154 , Score: 1000 , TEXT , SUMMARY , PDF

[2]
H.R. 872 (ih) To amend the Public Health Service Act to provide for human embryonic stem cell research, to direct the National Institutes of Health to issue guidelines for such stem cell research, and for other purposes. [Introduced in House]
Size: 6797 , Score: 839 , TEXT , SUMMARY , PDF

[3]
H.R. 877 (ih) To intensify stem cell research showing evidence of substantial clinical benefit to patients, and for other purposes. [Introduced in House]
Size: 7194 , Score: 745 , TEXT , SUMMARY , PDF

[4]
H.R. 873 (ih) To amend the Public Health Service Act to provide for human embryonic stem cell research. [Introduced in House]
Size: 3242 , Score: 544 , TEXT , SUMMARY , PDF

[DFLY]

A new STEMMIE in the house..PHYH PR invested into BMSN..heres PR..cheap too imo maybe pennies soon? company has cash too i dont think they have any debt either if im not mistaken phyh.

Phyhealth Announces Stem Cell Technology Investment
Feb 26, 2009 12:50:00 PM
Copyright Business Wire 2009



MIAMI--(BUSINESS WIRE)-- Physicians Healthcare Management Group, Inc. (Phyhealth) (Pink Sheets: PHYH), a developer of health maintenance organizations (HMOs) in partnership with physicians, today announced that it has purchased 1.3 million common shares and 25,000 preferred shares of Bio-Matrix Scientific Group, Inc. (Bio-Matrix) (OTCBB: BMSN) in a private transaction. Bio-Matrix Scientific Group, Inc., based in San Diego, provides stem cell related services and cryogenic storage, along with the development of instruments and procedures aimed at improving quality of life issues.

Mr. Robert Trinka, Chairman and CEO of Phyhealth, stated, "Given our solid cash position, we continue to target strategic investments that will help increase value for our shareholders, while remaining focused on our core mission of delivering high quality healthcare through our innovative community health plan model. Bio-Matrix is at an important inflection point in their development, as evidenced by their recently announced strategic relationships with several leading stem cell companies, which we expect will contribute to revenue growth in the months ahead. This transaction is representative of our commitment to explore and offer leading edge healthcare technologies designed to maintain the good health of our community health plan members and provide innovative, cost effective treatments for their disorders."

"The new administration has placed a high priority on developing new healthcare treatment technologies and has announced its full support of stem cell research," continued Mr. Trinka. "We believe our relationships with companies such as Bio-Matrix, at the forefront of new healthcare solutions, will offer Phyhealth members greater access to promising new treatment technologies such as stem cell therapy."

About Bio-Matrix Scientific Group, Inc.

Bio-Matrix Scientific Group, Inc. is a biotech research and development company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market. Bio-Matrix's new 15,000 sq. ft. facility, located in the heart of San Diego's biotechnology corridor, houses the company's two secure Cryogenic Stem Cell Banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing laboratory, hematology, microbiology and flow cytometry laboratories. The company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation.

About Physicians Healthcare Management Group, Inc.

Phyhealth is a developer of fully integrated healthcare organizations in partnership with physicians. Phyhealth Plans preserve the physician-patient relationship in order to deliver high-quality affordable healthcare within its selected communities. Phyhealth offers a turnkey, prepaid health plan solution to physicians for their Medicare and other individual patients who prefer to choose their own doctor and who make their own healthcare insurance purchasing decisions. Phyhealth Plans are unique in integrating all aspects of the delivery and financing of care, including providing medical liability insurance protection through Physhield Insurance Exchange, Phyhealth's exclusive risk retention group. The Phyhealth model empowers physicians to proactively manage their patient's general health and medical care and enhances physician financial rewards by increasing practice revenues, reducing expenses and restoring the economic value (equity) of their medical practices.

Forward-Looking Statements

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Physicians Healthcare Management Group, Inc, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results. Additional information is available at: http://www.phyhealth.com.




Source: Physicians Healthcare Management Group, Inc.


----------------------------------------------
For Phyhealth:
Crescendo Communications
LLC
David K. Waldman
212-671-1020
[e-mail]

[DFLY]

NBS nice pr today imo>>NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
Feb 23, 2009 9:08:00 AM


License enhances NeoStem's Presence in Anti-Aging Arena


NEW YORK, Feb. 23 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Alternext US: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has signed a license agreement to obtain the exclusive worldwide rights to innovative stem cell technology and applications for cosmetic facial and body procedures and skin rejuvenation.


The licensed technology, which includes an issued as well as pending patent application, was developed by Vincent C. Giampapa, M.D., F.A.C.S., a Board-certified plastic reconstructive surgeon and Assistant Clinical Professor of Plastic and Reconstructive Surgery at the University of Medicine and Dentistry of New Jersey. Dr. Giampapa, one of the first certified anti-aging medical physicians in the world, is Director of the Plastic Surgery Center Internationale and The Giampapa Institute for Anti-Aging Medical Therapy.


"We are extremely pleased to sign this agreement with Dr. Giampapa," said Robin Smith, MD, CEO of NeoStem, "Acquisition of the exclusive worldwide rights to these innovative stem cell skin rejuvenation procedures enhances NeoStem's leadership in the anti-aging and regenerative medicine arena. This has long been one of our core pursuits. Our earliest stem cell collection center is focused on treatments for physical aging. Recently, we agreed to acquire through a series of contractual arrangements, control over Shandong New Medicine Research Institute of Integrated Traditional and Western Medicine Limited Liability Company, a China limited liability company. Shandong is a leader in integrated traditional and western medicine in the People's Republic of China, and provides a multitude of treatments including cell regenerative therapies."


In January 2009, Dr. Giampapa presented and demonstrated some of his skin rejuvenation techniques using autologous adult stem cells at the 2009 International Stem Cell Technology and Applications Summit in Qingdao, China. His demonstrations were televised by China Central Television (CCTV), attracting wide public interest as well as professional interest from the Summit's audience of leading stem cell practitioners.


Dr Smith noted, "The excitement these new treatments are generating in China open strong new potential for NeoStem in the field of age management. Just as we envision Shandong as creating a destination treatment site for people seeking new clinical advances not yet available in their own home countries, we believe our ability to make widely available our new proprietary regenerative therapies in the United States will attract many people from China and around the world seeking safe and effective treatment here.


About NeoStem, Inc.

NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times for future medical need. The Company has also recently entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.


For more information, please visit: www.neostem.com.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results, including the successful closing of the Shandong transaction, the realization of the potential strategic benefits of the transaction and the realization of potential benefits from the acquisition of its new licensed technology, could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Contact:
NeoStem, Inc.
Robin Smith, Chief Executive Officer
T: 212-584-4180
E: [e-mail]
www.neostem.com



SOURCE Neostem, Inc.



----------------------------------------------
Robin Smith
Chief Executive Officer
NeoStem
Inc.
[phone]
[e-mail]

[DFLY]

ISCO nother solid pr today...these guys got the funding they needed and now really moving forward quickly imo..lookin fer dollar break soon..

DiscoveryBioMed, Inc. Engaged in Multiple Projects on Behalf of Lifeline Cell Technology, Inc. to Test the Function and Utility of Multiple Primary Human Cell Products
Lifeline Cell Technology Products Being Used As Models for Drug Testing
Feb 19, 2009 8:15:00 AM
Copyright Business Wire 2009



BIRMINGHAM, Ala. & OCEANSIDE, Calif.--(BUSINESS WIRE)-- DiscoveryBioMed, Inc. has agreed to move forward with a "service" contract for primary human cell bioassay testing for its first commercial client, Lifeline Cell Technology, Inc., a wholly owned subsidiary of International Stem Cell Corporation (OTCBB: ISCO).

"This is a mutually beneficial relationship between two companies that believe in the development, use, and sale of human cells as the most important and biologically relevant reagents for experimental systems," said Dr. Erik Schwiebert, CEO of DBM, Inc. "Lifeline Cell Tech is also our first commercial client and these contracts provide a wonderful opportunity for our company to generate knowledge about human cell physiology as well as early revenue."

"We agree that human cells are critically important in-vitro models to assure drug safety and conduct basic research," said ISCO President and Lifeline Cell Technology CEO Jeffrey Janus. "DiscoveryBioMed's proven expertise in assay development combined with Lifeline's expertise in producing optimized human adult and stem cell products will certainly result in powerful research tools."

In addition to these introductory interactions, DBM and Lifeline Cell Tech are developing a mutual SBIR grant proposal on the use of multiple human cell cultures derived from different tissues as an important in vitro platform for testing pollutant, candidate therapeutics and existing drugs for toxicity against cells in a variety of human tissues.

ABOUT DISCOVERYBIOMED, INC.

DiscoveryBioMed, Inc. is a life sciences and biotechnology company that engages in R&D and services work in cell engineering and production and drug discovery. The company is located within Innovation Depot in Birmingham. Using physiologically relevant cell culture models preferably derived from normal and diseased adult human cells and tissues, it focuses on finding therapeutic compounds for a variety of human diseases. It also applies this custom human cell-based approach to its "fee-for-service" support to researchers in allied areas and currently serves clients both locally in Alabama as well as in 8 other states in the US currently. For more information, visit the DBM website at www.discoverybiomed.com.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California biotechnology company focused on developing therapeutic and research products. ISCO's technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will minimize immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true "Stem Cell Bank" and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at: www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

For more news and information on International Stem Cell Corporation, please visit www.IRGnews.com/coi/ISCO where you can find the CEO's video, a fact sheet on the company, investor presentations, and more.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated future financial and/or operating results, future growth in research, technology, clinical development and potential joint venture and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.



Source: International Stem Cell Corporation


----------------------------------------------
DiscoveryBioMed
Inc.
Erik Schwiebert
Ph.D.
CEO
[e-mail]
or
International Stem Cell Corporation
Jeffrey Janus
President
[e-mail]
760-940-6383
or
The Investor Relations Group
212-825-3210
Investor Relations:
Adam S. Holdsworth
[e-mail]
or
Media Relations:
Laura Colontrelle
[e-mail]

[uw86]

negative development:
http://www.breitbart.com/article.php?id=D96DLTT00&show_article=1

[swanlinbar]

Obama Poised to Reverse Bush's Taliban-Like, Big Brother Stem Cell Policy
February 17, 2009 11:45 AM ET | Bonnie Erbe | Permanent Link | Print
By Bonnie Erbe, Thomas Jefferson Street blog

I've certainly criticized President Obama enough since he's taken office and even more when he was a presidential candidate. But I don't hesitate to applaud him when he does something right. One of his advisers told a Sunday television talk show that the president is on the precipice of overturning yet another Bush administration policy that pushed us back. George W. Bush's stem cell policy pushed us so far back, in fact, that when the Clinton administration ended in 2000, we felt like a country moving forward. When Mr. Bush left office last month, he'd pushed the country back to the 1950s.

"In 2001, Bush limited federal funding for stem cell research only to human embryonic stem cell lines that already existed. It was a gesture to his conservative Christian supporters who regard embryonic stem cell research as destroying potential life, because the cells must be extracted from human embryos. Embryonic stem cells are the most basic human cells which can develop into any type of cell in the body. Scientists believe the research could eventually produce cures for a variety of diseases, including Parkinson's disease, diabetes, heart disease and spinal cord injuries."

President Bush's kowtowing to the religious right pushed us so far back in terms of social policy, it felt as if the United States had somehow morphed into Afghanistan during the Taliban's reign. Many of us felt repressed by the government, because of both the injection of religion and morality into law and the feeling that Big Brother was watching our every move for no good reason.

Note the verbiage used in the Reuters article above, which says that the Christian right opposed stem cell research because its members see use of embryonic stem cells as destruction or murder of "potential life." These people need to get a life. They care more about potential life than actual living, breathing, grown-up human beings. They are costing lives while pretending to campaign as pro-lifers.

On Facebook? You can keep up with Thomas Jefferson Street blog postings through Facebook's Networked Blogs.

Read more by Bonnie Erbe.
Read more from the Thomas Jefferson Street blog.
Read more about stem cells.

[swanlinbar]

Just got a reply from VODG-Dear Mr XXXXXXXXWe recently filed Form 8-K with the SEC and our Form 10KSB is due to be filed shortly.



Thank you for your interest.



Best regards,

Jim Musick, Ph.D.

President and CEO

Vitro Diagnostics, Inc.

[DFLY]

gettin a E tomorrow btw..delinquent filing..jus a fyi..eom

[swanlinbar]

VODG -Experienced Cancer Researcher Joins Vitro's Scientific Advisory Board
Feb 17, 2009 8:00:00 AM

Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced the appointment of Dr. Pamela L. Rice to its Scientific Advisory Board. Dr. Rice holds a Ph.D. in Molecular Toxicology from the Department of Pharmaceutical Sciences at the University of Colorado and a B.S. degree in genetics from the University of California at Davis. She is presently an Assistant Professor in the Department of Medicine at the University of Colorado Health Sciences Center where she leads a team of researchers in her own laboratory that conducts grant-supported cancer research focusing on mechanism-based novel therapies.

Dr. Rice has authored numerous peer-reviewed papers in her nearly 20-year career as a cancer researcher in journals including "Cancer Research" and "Molecular Cancer Therapeutics." Her research includes detailed studies of the mechanisms of cancer cell death induced by non-steroidal anti-inflammatory drugs and novel therapeutic targets for colon cancer. The latter includes pathways involved in regulating cell proliferation and cell survival.

Dr. Rice will provide Vitro with consultation in the development of its stem cell products and technology for application to cancer research and treatment. Dr. Rice said, "I am excited to have the opportunity to apply my extensive experience and expertise to assist Vitro in the development of novel stem cell-based products for the fight against cancer. Cellular-mediated destruction of cancer stem cells represents a promising new avenue for the development of effective treatments that specifically target cancer stem cells. This is important because new ways to attack difficult to treat cancers continue to involve stem cell-mediated mechanisms. Additionally, these new products would minimize side-effects of standard chemotherapy. The products that Vitro is developing may provide cancer researchers with more selective tools to advance this very important new approach to cancer treatment."

Vitro owns issued US patents for production of FSH, a fertility drug, immortalization of cells and recently received a Notice of Allowance for its patent for generation of adult stem cells. In addition, the Company has another pending US patent regarding stem cell-based cancer treatments.

Dr. Joe Nieusma, also a member of Vitro's SAB and consultant to Vitro, said, "I am enthusiastic about the appointment of Dr. Rice to Vitro's SAB and scientific team. Her background in cancer research, cell culture and in vivo mechanistic work provides tremendous expertise that complements Vitro's existing talents and will aid in advancing the excellent stem cell research program already in existence. I anticipate synergy between Dr. Rice and Vitro that will accelerate development of novel stem cell-based cell therapies for cancer, especially traditionally poor prognosis cancers such as pancreatic, lung and brain."

[DFLY]

Stemmies lightin up as the Stem Cell conference is underway already been covered by cnbc a few times today already. CYTX was one they were talking about. Now when the ban gets lifted look out above for most all stemmies imo!)

[odinpinetree]

Axelrod: Stem cell order coming soon from Obama

http://townhall.com/news/politics-elections/2009/02/15/axelrod_stem_cell_order_coming_soon_from_obama

Expect an executive order soon from President Barack Obama on federal funding for embryonic stem cell research.

That's the word from White House adviser David Axelrod.

Under President George W. Bush, federal money for research on human embryonic stems cells was limited to those stem cell lines that were created before Aug. 9, 2001. No federal dollars could be used on research with cell lines from embryos destroyed from that point forward.

Federal rules do not restrict embryonic stem cell research using state or private funds.

Obama made it clear during the campaign he would overturn Bush's directive.

Axelrod tells "Fox News Sunday" that Obama right now is considering an executive order lifting the federal ban on funding.

Stem cells are the building blocks that turn into different kinds of tissue.

[swanlinbar]

A Birthday Gift for Darwin
by David Ewing Duncan | See Archive
Two hundred years after the author of On the Origin of Species was born, President Obama is poised to fund embryonic stem cell research, while 54% of Americans still scoff at evolution.
Will President Obama recognize Charles Darwin's 200th birthday by lifting federal funding restrictions for embryonic stem cell research?

The symbolism couldn’t be riper: a newly installed, pro-science president signs a promised executive order overturning his predecessor’s anti-stem cell policy on this day and in this year, which also celebrates the 150th anniversary of Darwin’s seminal work, On the Origin of the Species.

Already, the half of Americans that profess to deny Darwin’s central theory of evolution are cringing at this birthday being celebrated by the other half who do believe. Many of the nonbelievers also oppose embryonic stem cell research, although this number has been dropping, particularly as treatments and cures using these special cells inch ever closer.

Just a few days ago, the Food and Drug Administration approved the first-ever human tests using embryonic stem cells, those cells formed in an embryo soon after conception that can grow into any tissue in the body. Geron Corporation of Menlo Park, California will implant stem cells in up to eight paraplegics in effort to repair their spinal chord injuries.

If all goes well, the stem cells will help repair a material around nerve cells known as myelin, which should restore the ability of nerve cells to carry signals and to function. Some cells may also be spurred to regenerate.

Other companies are poised to begin testing embryonic stem cell treatments for a market that analysts say could equal over $8 billion by 2016 – including therapies derived from “adult” stem cells, those taken from fully-formed humans to regenerate specific cells in the heart, pancreas, and elsewhere.

It seems eons ago that President George W. Bush signed an executive order in 2001 limiting federal funding for embryonic stem cell research, a move applauded by the religious right who consider human life to begin at conception. Critics have long complained that this move crippled crucial research, delayed therapies, and caused unneeded suffering and death.

In 1859, Charles Darwin had no idea that stem cells existed, and that they are the crucial building blocks developed by complex organisms over the course of billions of years to launch the process of creating a person – or a toad, falcon, spider, and guppy.

He also might be astonished that his theory is denied by millions of people – by 54 percent of Americans, and more than half of his own countrymen in Britain, according to a recent poll.

Perhaps this is understandable at one level, since Darwin challenges our fundamental view of the place of humans in the universe. If God created us, then we are special. If we are descended from bacteria, pufferfish and chimpanzees, we are merely another organism.

This sort of thinking misses the point about Darwin’s enduring theory: that understanding the progression of life for some 3.5 billion years on Earth is fascinating in its complexity and diversity. It also provides us the tools to understand the wonders of stem cells, which finally, after years of being starved of federal funding, are poised to be unleashed.

[swanlinbar]

Added more VODG yesterday,Very Good article here:Examine the Stem Cell Therapeutics Markets
Thursday February 12, 2009, 12:02 pm EST
Yahoo! Buzz Print NEW YORK--(BUSINESS WIRE)--Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue.

Stem Cell Therapeutics Markets

http://www.reportlinker.com/p0102144/Stem-Cell-Therapeutics-Markets.html

Political and business events presage change for stem cell therapeutics, most notably the expected move by President Barack Obama to lift federal funding restrictions on stem-cell research. The U.S. Congress has also indicated a desire to move forward with stem cell research. The momentum in two branches of American government, along with scientific developments and the competition of world markets presages good market conditions for stem cell research.

With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells.

While companies have found opportunity outside the U.S., President Bush's seven year limitations on embryonic stem cell research in the U.S. has For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells Therapeutics Markets Kalorama analyst Alison Sahoo has built models to determine the best case and most likely case scenarios for therapeutic markets for stem cells in the coming years. This report breaks down forecasted revenues and procedure volumes for stem cell technologies for these segments in the following disease areas:


Cardiovascular disease
Lung disease
Arthritis
Incontinence
Osteoporosis
Diabetes
Cancer
Orthopedics
Infertility
Alzheimer’s disease
Burns (severe)
Lupus
Parkinson’s disease
Liver failure
Multiple sclerosis
Critical limb ischemia
Crohn's disease
Sickle cell disease
Multiple myeloma
NH lymphoma
Leukemia

Ths report is the result of exclusive interviews with executives in the stem cell industry, a review of medical and company literature, government databases and publications. As part of this comprehensive analysis of stem cell markets, the following companies were profiled:


Aastrom Biosciences
Advanced Cell Technologies
Brainstorm Cell Therapeutics
Celegene
ES Cell International
Medistem
Neostem
Opexa Therapeutics
Osiris Therapeutics
Plureon
Regenetech
Revivicor
Stem Cell Sciences
StemLifeLine
ThermoGenesis
VetCell Bioscience

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY


Recent Developments
Introduction
Current Stem Cell Therapies
Developmental Stem Cell Therapies
Issues in Stem Cell Research
Stem Cell Forecasts
Market Forecast
The Promise of Stem Cells in Medical Treatment
Types of Stem Cells
Embryonic Stem Cells
Important Developments in ES Cell Research
Adult Stem Cells
Important Developments
Scope and Methodology

CHAPTER TWO: CURRENT STEM CELL THERAPIES


Cancer
Leukemia
Gene Therapy
Multiple Myeloma
Non-Hodgkin’s Lymphoma Noncancerous Diseases
Aplastic Anemia
Immunodeficiency
Lupus
Sickle Cell Disease
Other Conditions

CHAPTER THREE: DEVELOPMENTAL STEM CELL THERAPIES


Alzheimer’s Disease
Arthritis
Burns
Cancer
Cardiovascular Conditions
Critical Limb Ischemia
Crohn’s Disease
Diabetes
Incontinence
Infertility
Liver Failure
Lung Disease
Multiple Sclerosis
Orthopedics
Osteoporosis
Parkinson’s Disease
Sickle Cell Disease

CHAPTER FOUR: STEM CELL MARKET FORECASTS


Best Case
Forecasts By Disease Area
Alzheimer’s Disease
Arthritis
Burns
Cancer,
Cardiovascular Conditions
Critical Limb Ischemia
Crohn’s Disease
Diabetes,
Incontinence
Infertility,
Liver Failure
Lung Disease
Multiple Sclerosis
Orthopedics
Osteoporosis
Parkinson’s Disease
Sickle Cell Disease
Most Likely Case
Forecasts By Disease Area
Alzheimer’s Disease
Arthritis
Burns
Cancer,
Cardiovascular Conditions
Critical Limb Ischemia
Crohn’s Disease
Diabetes,
Incontinence
Infertility,
Liver Failure
Lung Disease
Multiple Sclerosis
Orthopedics
Osteoporosis
Parkinson’s Disease
Sickle Cell Disease

CHAPTER FIVE: COMPANY PROFILES


Aastrom Biosciences
Advanced Cell Technologies
Athersys
Brainstorm Cell Therapeutics
Celegene
ES Cell International
Medistem
MultiCell Technologies, Inc.
Neostem
Nephros Therapeutics, Inc.
Opexa Therapeutics
Osiris Therapeutics
Plureon
Regenetech
Revivicor
Stem Cell Sciences
ThermoGenesis
VetCell Bioscience

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY


Table 1-2: Stem Cell Therapeutics Market in $ Millions, 2007-2020

CHAPTER TWO: CURRENT STEM CELL THERAPIES


Table 2-1: Types of Leukemia, 2007

CHAPTER THREE: DEVELOPMENTAL STEM CELL THERAPIES


Table 3-1: Global Disease Populations Addressed by Potential Stem Cell Therapies, 2007
Table 3-2: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
Table 3-3: Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2007 and 2020
Table 3-4: Types and Features of Urinary Incontinence, 2007
Table 3-5: Types and Causes of Male Infertility, 2007
Table 3-6: Common Diseases of the Lungs, 2007

CHAPTER FOUR: STEM CELL MARKET FORECASTS


Table 4-1: Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2007
Table 4-2: Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)
Table 4-3: Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007 - 2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)
Table 4-4: Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)
Table 4-5: Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007-2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)

CHAPTER FIVE: COMPANY PROFILES


Table 5-1: Therapeutic Focus of Selected Stem Cell Therapeutics Companies, 2007

To order this report:

Stem Cell Therapeutics Markets

http://www.reportlinker.com/p0102144/Stem-Cell-Therapeutics-Markets.html

More market research reports here!


Contact:
Reportlinker
Nicolas: [e-mail]
US: (805)-652-2626

[swanlinbar]

Doctors implant stem cells to revive kid's lost vision
12 Feb 2009, 0217 hrs IST, Malathy Iyer, TNN

Print Email Discuss Share Save Comment Text:



MUMBAI: As Pratik Patil babbles into the pay phone, there is little to indicate that the 27-month-old has been living out of hospitals for over a
year. His opaque left eye tells a different story though -- his impaired vision is obvious.

On Wednesday, doctors at Bombay Hospital in New Marine Lines announced that they were trying out a new stem cell therapy to restore vision to his affected eye. "In six months, we will know whether he can see or needs a corneal transplant,'' said Dr Sonia Nankani of the hospital's Taparia Opthalmology Centre.

Son of a farmer, Pratik's saga began 18 months ago in Kagar village of Kolhapur. "We noticed his bloody stool and went to the taluka hospital,'' said his father Arun on Wednesday. The child went to several hospitals before undergoing a four-month-long treatment for TB of the intestines at Nair Hospital, Mumbai Central.

"The condition returned and we rushed back to Mumbai,'' Pratik's father said. Though the toddler was soon cured of TB, his left eye suddenly appeared dry and developed a reddish rash. After making rounds of hospitals, they were referred to Dr Nankani, a cornea expert, on December 17 last year.

"I realised he had a stem cell deficiency,'' said Dr Nankani. Limbal stem cells, which are present on the rim of the eyes, keep the eyes moist. An injury or as in Pratik's case, malnutrition brought on by a disease, results in xerosis or dry eye. "As the cornea becomes dry, vision is affected,'' she said.

What followed was a new protocol: instead of directly transferring limbal cells from Pratik normal eye to the other eye, the doctor took a 2mm slice of the cells to be cultured (grown) in a city laboratory. "The laboratory multiplied his limbal cells on a special cell lining (see box).''

In the second week of January, the laboratory-grown membrane was transferred to Pratik's left eye. "It has been a month now and we are happy with the progress. It will take another six months for the final result,'' she said. Even if Pratik needs a cornea transplant, the stem cell therapy will ensure better results.

Bombay Hospital's spokesperson Dr Aashish Tiwari said Pratik was the youngest child in the city to have undergone the treatment after it got the FDA approval and became commercially available. "We paid Rs 44,000 to the laboratory for Pratik and have waived the child's hospital expenses,'' he said.

However, Dr T P Lahane, head of the opthalmology department of JJ Hospital, said he had attempted three such stem cell therapy cases but they had eventually failed. Dr Vandana Jain from Aditya Jyot Hospital performed the same procedure on three children successfully two years back. "It was part of a clinical trial. We are now waiting for donors to help us conduct the expensive procedure for other children,'' she said.



Click here to comment on this story.

[swanlinbar]

New technology sheds light on rise of blood cells
Wed Feb 11, 2009 3:01pm EST Email | Print | Share| Reprints | Single Page[-] Text [+]
LONDON (Reuters) - German scientists using new imaging technology said on Wednesday they have watched a single cell give rise to blood cells, bolstering understanding of stem cells.

The findings could one day allow scientists to create blood in the laboratory that hospitals could give to patients needing transfusions, said Timm Schroeder of the Institute of Stem Cell research in Munich.

"What we are looking at is where blood really comes from during development," he said in a telephone interview. "Blood cells are born during the embryo development and we wanted to know from what type of cells they came from."

The researchers, who published their findings in the journal Nature, developed technology that allowed them to track hundreds of thousands of cells in real time over a week.

Homing in thousands of endothelial cells, which line blood vessels, the researchers discovered that a subset was able to form blood cells.

"It is important to know the exact cell type that produces blood," Schroeder said. "This is the prerequisite to tweak the system to produce blood cells from embryonic stem cells in a lab."

Stem cells are the body's master cells, giving rise to various tissues and the blood. Some types are found throughout organs, blood and tissue and are in immature form until they generate needed cell types.

Doctors hope to use them some day in a new field called regenerative medicine in which tailor-made transplants of tissues and perhaps organs can be grown from a patient's own cells.

(Reporting by Michael Kahn; Editing by Maggie Fox)





© Thomson Reuters 2009 All rights reserved

[rlwinvestor]

Article on http://tradingstemcells2009.blogspot.com gives an opinion on when trader/investors may want to exit out of the red hot stem cell names. It's not a bashing article, but it is good food for thought.

[index of ideas]

Howdy, hope you're all benefiting from these ups and downs.

I thought this board might find this site interesting since it keeps all the stem news for each day organized and in one place, great for research: http://www.stemcelltracker.com

There is a lot of news today!

[swanlinbar]

Bought some more VODG & MKRS today

[swanlinbar]

Scientists Heartened at Prospect of End to Stem Cell Ban
By Amanda Gardner
HealthDay Reporter
MONDAY, Feb. 9 (HealthDay News) -- Researchers are rejoicing over President Barack Obama's anticipated lifting of the eight-year ban on embryonic stem cell research imposed by his predecessor, President George W. Bush.

Latest MedicineNet NewsPossible End to Stem Cell Ban?
Minority Clinics Tougher on Doctors
Minorities Distrust Medical System More
Needed: Blood Donations
Smokers Have Rapid Aging Defect
Want More News? Sign Up for MedicineNet Newsletters!
The anticipation moved one step closer to reality Thursday, with media reports that Obama gave House Democrats at a closed-door Virginia retreat a "guarantee" that he would sign an executive order overturning Bush's policy.

"It's going to remove an embarrassment for American science," said Dr. Darwin Prockop, director of the Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine at Scott & White Hospital in Temple. "It's a statement that we're going to again believe in science."

Yet those same experts are aware that the sobering state of the economy could impose its own restrictions on this type of research.

"This clearly is a very important part of our medical future," said Paul Sanberg, distinguished professor of neurosurgery and director of the University of South Florida Center of Excellence for Aging and Brain Repair in Tampa. "[But] to clear the path for this without giving additional money to the National Institutes of Health will be disappointing. I hope the stimulus package also includes an increase in embryonic stem cell funding."

Sanberg also expressed concern that any monies redirected to stem cell research could divert funds from other critical avenues of research. "If it's a normal competitive process, it will take money away from other programs," he said.

Stem cell research received a big boost in January, when the U.S. Food and Drug Administration approved the first-ever human trial using embryonic stem cells as a medical treatment.

Geron Corp., a California-based biotech company, was given the OK to implant embryonic stem cells in eight to 10 paraplegic patients who can use their arms but can't walk.

In 2001, then-president Bush limited federal funding for stem cell research only to human embryonic stem cell lines that already existed.

The decision prompted some scientists to worry that the United States would fall behind other countries in the drive to unlock the potential of stem cell research.

Embryonic stem cells are the most basic human cells, believed to be capable of growing into any type of cell in the body. Working as a sort of repair system for the body, they can theoretically divide without limit to replenish other cells. The scientific hope is that stem cells may, at some point in the future, become capable of treating a variety of diseases and conditions, such as Parkinson's disease, diabetes, heart disease and spinal cord injuries, according to the U.S. National Institutes of Health.

National polls continue to find that the majority of Americans favors embryonic stem cell research, although some surveys have found that that support has declined somewhat in recent years.

Many people object to the use of embryonic stem cells, contending that the research requires the destruction of potential life, because the cells must be extracted from human embryos.

The stem cells being used in the recently approved Geron trial were obtained from one of the Bush administration's approved stem cell lines. And no federal funds were used in the development of this treatment.

Since the restrictions on embryonic stem cell research took effect, many research institutions have redirected their focus to other types of stem cells. Prockop's institution, for instance, deals only with adult stem cells.

Adult stem cells can give rise to all the specialized types of cells found in tissue from which they originated, such as skin. But, scientists don't agree on whether adult stem cells may yield cell types other than those of the tissue from which they originate, according to the National Institutes of Health.

Prockop said embryonic stem cells "are mainly of interest as a research tool and a biological experimental system. Their use in patients in spite of that recent approval for Geron is really very questionable because of the potential for tumors."

Still, the anticipated lessening of restrictions by the Obama administration may help funnel more private money into stem cell research, the experts said.

"This should give more general acceptance to stem cell research, because now, there won't be this stigma associated with it as much," Sanberg said.

And, perhaps, a new federal policy would spur organizations such as the American Heart Association -- which currently does not fund research involving human embryonic stem cells or stem cells derived from fetal tissue -- to channel funds into this line of research, Sanberg added. (The heart association said it "recognizes the value of all types of stem cell research and supports federal funding of this research.")

Still, Sanberg pointed out, some ethical issues surrounding stem cell research and its application will remain.

For instance, he said, "There still needs to be some oversight on the uses of stem cells and cloning."


SOURCES: Paul Sanberg, Ph.D., D.Sc., distinguished professor of neurosurgery, and director, University of South Florida Center of Excellence for Aging and Brain Repair, Tampa; Darwin Prockop, M.D., Ph.D., director, Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine at Scott & White Hospital, Temple, Texas; American Heart Association

Copyright © 2009 ScoutNews, LLC. All rights reserved.

[DFLY]

nice!!!)thanks for posting that..)eom

[AugustaFriends]

Obama 'guarantees' stem cell approval

http://washingtontimes.com/news/2009/feb/06/obama-guarantees-aiding-stem-cell/

Friday, February 6, 2009
Obama 'guarantees' stem cell approval
Stephen Dinan (Contact)
WILLIAMSBURG| President Obama on Thursday gave lawmakers his "guarantee" he will sign an executive order overturning President Bush's embryonic stem cell research policy.

Meeting with House Democrats holding a retreat here, Mr. Obama answered a question from Rep. James R. Langevin, a Rhode Island Democrat who is a paraplegic, by saying he will sign the order, according to three sources who were in the closed-door part of the meeting.

"I guarantee you that we will sign an executive order for stem cells," Mr. Obama said, according to the sources who requested anonymity because they were not authorized to talk about the closed-door portion of the meeting.

Mr. Obama said the executive order would be coordinated with Congress on timing, and said it was important that Congress also pass a law codifying his order so that a future president couldn't simply reverse the policy back.

In 2001, Mr. Bush signed an order early in his presidency allowing federal funding for embryonic stem cell research, though limiting it only to lines that existed at that point. Congress has twice passed a bill expanding funding beyond Mr. Bush's policy but he vetoed it, and lawmakers were unable to override it.

The research is theoretically promising because embryonic stem cells can turn into any kind of human cell, which holds out the possibility of miracle cures via the production of patient-specific healthy cells untainted by disease or degeneration.

However, harvesting the cells destroys the embryo, which has raised moral criticism of the research as a form of murder the reason for Mr. Bush limiting the research to lines where the decision about life and death already had been made. Research done outside U.S. federal auspices also has yielded few tangible results.

In Williamsburg, the private Q&A portion Mr. Obama spoke in public for 22 minutes about his stimulus spending bill, ditching his prepared remarks for much of the time to deliver a fiery plea to Democrats and a mocking rebuke to Republicans.

He blamed "cable chatter" for distorting the debate, and said, "aren't you all tired of that stuff?"

"I don't care whether you're driving a hybrid or an SUV, if you're headed for a cliff you've got to change direction," he said. "That's what the American people called for in November, and that's what we intend to deliver."

In fielding questions, Mr. Obama was asked how he planned to keep his millions of supporters engaged going forward, and he said he was counting on the Democratic National Committee to manage that effort. He said he was about to launch "Obama 2.0."

It was the president's first trip out of Washington since being inaugurated, and marked his first flight as president aboard Air Force One. He came back to the press cabin at the back of the plane to talk with reporters as the plane was taxiing for liftoff, and he was sporting a brand new blue Air Force One crew jacket with his name stitched on the breast.

"I’ve got my spiffy jacket so I thought I’d come and show it off," he said.

"It’s good to see you guys. What do you think about this spiffy ride? It’s not bad," he told the press, who he visited in their rear compartment before the flight took off.

He also raved about the view from Marine One, which ferries the president from the lawn of the White House to Andrews Air Force Base, where Air Force One always awaits him.

"The helicopter was very smooth, very impressive, you go right over the Washington Monument and then, you know, kind of curves in by the Capitol. It was spectacular."

[Zoofire]

http://washingtontimes.com/news/2009/feb/06/obama-guarantees-aiding-stem-cell/

[swanlinbar]

MCET Stem cells interesting from the 10K:

In April, 2005, the Company was granted US Patent # 6872389 for the liver stem cell invention of Dr. Ron Faris, MultiCell’s Senior Vice President and Chief Scientific Officer. This patent contains twenty-four claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to the Company’s adult stem cell portfolio. The Company has an exclusive, long-term license agreement with Rhode Island Hospital for use of the following patents owned by the hospital related to liver cell lines and Liver Assist Devices (LADs):


US Patent #6,017,760, Isolation and Culture of Porcine Hepatocytes, expires October 9, 2015;
US Patent #6,107,043, Immortalized Hepatocytes, expires February 8, 2019;
US Patent #5,043,260, Perfusion Device for Hepatocytes, expires August 27, 2008;
US Patent #6,129,911, Liver Stem Cell, expires October 10, 2017;
US Patent # 6,858,146 Artificial Liver Apparatus and Method (Sybiol), expires on February 20, 2019; and
US Patent # 6,872,389 Liver Stem Cell expires on July 8, 2019.

[DFLY]

thanks for the DD Augusta much preciated!)Stem cells for 09 weeeeeeeeeee lol!)

[06mets]

PSTI IS A BUY, guaranteed to bounce hard big time imo, mark this post , currently at 1.60, this will go north fast

[uw86]

scii: the reverse split confirmed in the SEC filings late 08; 1/3 split assuming the deal goes through

[swanlinbar]

Wasn't the SCII R/split to happen last june,do you have a date for R/S? Thanks

[up-down]

ATHX chart / some DD

AS: 100M
OS: 19M
Revenue (ttm): 3.64M

http://sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Athersys

Lot of recent form-4's from the CE who has been buying (code "P")



Not a pure Stem Cell play.

Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic product candidates in multiple disease areas in the United States. Its product pipeline includes ATHX-105, a Phase I clinical trial product for the treatment of obesity. The company also develops orally active pharmaceutical products for the treatment of central nervous system disorders that include sleep disorders, such as narcolepsy or excessive daytime sleepiness; and other potential indications comprising attention deficit hyperactivity disorder and other cognitive disorders. In addition, Athersys, through its product co-development collaboration with Angiotech Pharmaceuticals, Inc., develops MultiStem for the treatment of damage caused by myocardial infarction and peripheral vascular disease, as well as for hematopoietic stem cell transplant support, ischemic stroke, and other disease indications. The company was founded in 1995 and is based in Cleveland, Ohio.

----

We are a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Through the application of our proprietary technologies and core capabilities, we have developed a pipeline of therapeutic product development programs in multiple diseases and conditions. We have established drug development programs in the areas of obesity and central nervous system disorders. In addition, applying our proprietary cell therapy platform, MultiStem®, we have established therapeutic product development programs in the areas of cardiovascular disease and hematopoietic stem cell transplant support, as well as other areas.

---

Our sources of liquidity include our cash balances and available-for-sale securities. At September 30, 2008, we had $14.7 million in cash and cash equivalents and $20.0 million in available-for-sale securities. We expect to have available cash to fund our operations into 2010 based on our current business and operational plans and assuming no new financings. We have primarily financed our operations through private equity and debt financings that have resulted in aggregate cumulative proceeds of approximately $200 million.

----

Investors in our equity offering in June 2007 received five-year warrants to purchase an aggregate of 3,250,000 shares of common stock with an exercise price of $6.00 per share. The lead investor in the June offering, Radius Venture Partners, invested $10.0 million in the June offering and received additional five-year warrants to purchase an aggregate of 500,000 shares of common stock with a cash or cashless exercise price of $6.00 per share. The placement agents for the June offering received five-year warrants to purchase an aggregate of 1,093,525 shares of common stock with a cash or cashless exercise price of $6.00 per share. The exercise of such warrants could provide us with cash proceeds. No warrants were exercised at September 30, 2008.

----

In connection with our 2006 MultiStem collaboration with Angiotech, Angiotech purchased subordinated convertible promissory notes in the aggregate principal amount of $10.0 million, which were converted along with accrued interest into common stock upon the closing of our equity offering in June 2007. Upon the successful achievement of specified clinical development and commercialization milestones, we may also receive up to $3.75 million of additional equity investments and $63.75 million of aggregate cash payments, though there can be no assurance that we will achieve any milestones.

----

Our senior loan was repaid in full in June 2008. The senior lenders retain a right to receive a milestone payment of $2.25 million upon the occurrence of certain events as follows: (1) the entire amount upon (a) the merger with or into another entity where our stockholders do not hold at least a majority of the voting power of the surviving entity, (b) the sale of all or substantially all of our assets, or (c) our liquidation or dissolution; or (2) a portion of the amount from proceeds of equity financings not tied to specific research and development activities that are part of a research or development collaboration, in which case, the senior lenders will receive an amount equal to 10% of proceeds above $5.0 million in cumulative gross proceeds until the milestone amount is paid in full. The milestone payment is payable in cash, except that if the milestone event is (2) above, we may elect to pay 75% of the milestone in shares of common stock at the per-share offering price. No milestone events occurred in the nine-month period ended September 30, 2008. The senior lenders also received warrants to purchase 149,026 shares of common stock with an exercise price of $5.00 upon the closing of our equity offering in June 2007. The exercise of such warrants could provide us with cash proceeds. No warrants were exercised at September 30, 2008. We are considering entering into a new debt facility in 2008 or 2009, although we cannot assure you that such funding will be available to us or, if available, that it will be available on acceptable terms, particularly in light of the current credit crisis.

[pnnymn]

ATHX the ONLY stem cell stock trading BELOW cash......$1.70 cash per share

[CiscoTrader]

Great find could mean it's in the near future of going up up and away? imo

[mrinos]

cbai partners with BlueCross
http://www.msbcbs.com/corcell/members.html

[Epic]

Yeah looking at the past history on the chart it ran from .25 to over a buck $$$$$$$$ last time

[SFGiants]

BCLI will be hitting 50 very short term...im thinking ~1.20 by mid March

[Epic]

kgeezy I agree 100% on BCLI I picked up some on Friday and will be buying more on Monday. I think it could make a run for .50. Love to see the company release some news

[SFGiants]

BCLI will give you plenty of green IMO...set to runnnnnnnnn

[Epic]

Looking for another green week in stem plays as momo continues to climb.

[MrBigz]

BCLI gonna run BIG IMO

O/S under 50 million - huge volume on Friday

[$ubmachine]

Thx, good stem cell information!

[AugustaFriends]

Thank you BH, just as any son worried and hurting.. Thanks..

[AugustaFriends]

Stem Cell 101 http://investorshub.advfn.com/boards/read_msg.aspx?message_id=35224670

[Bull Trader]

sorry to hear that bud. I hope she is going to be fine until they can find a cure or better treatment. i believe we will be seeing some major breakthroughs in stem cell technology/application in the coming months/years....so rest easy!